Arjun  Agarwal net worth and biography

Arjun Agarwal Biography and Net Worth

Bringing a wealth of experience, he previously held the position of Vice President of Finance at Jasper Therapeutics from June 2021 to March 2024. During his tenure at Jasper, he played a pivotal role in facilitating the company’s successful transition to a publicly traded entity, contributing significantly to its strategic positioning and navigating multiple rounds of financing. Prior to his role at Jasper, he served as Vice President, Corporate Controller, at Protagonist Therapeutics, a publicly held company, for two years. His extensive background also includes a decade-long tenure at McKesson Corporation, where he held various leadership roles in finance and accounting. At McKesson, he played a key role in driving strategic initiatives, managing mergers and acquisitions, and ensuring seamless financial integration of newly acquired businesses. Before his corporate roles, he gained invaluable experience at PricewaterhouseCoopers (PwC), where he worked for nine years across their San Jose, California, and Mumbai, India, offices.

Arjun is a graduate of Sydenham College of Commerce and Economics at Mumbai University, India. He is a Certified Public Accountant (CPA) and a Chartered Accountant accredited by the Institute of Chartered Accountants of India.

What is Arjun Agarwal's net worth?

The estimated net worth of Arjun Agarwal is at least $1.16 million as of June 15th, 2026. Agarwal owns 16,899 shares of Oruka Therapeutics stock worth more than $1,163,665 as of June 15th. This net worth estimate does not reflect any other investments that Agarwal may own. Learn More about Arjun Agarwal's net worth.

How do I contact Arjun Agarwal?

The corporate mailing address for Agarwal and other Oruka Therapeutics executives is 10170 CHURCH RANCH WAY SUITE 100, WESTMINSTER CO, 80021. Oruka Therapeutics can also be reached via phone at 720-940-2100 and via email at [email protected]. Learn More on Arjun Agarwal's contact information.

Has Arjun Agarwal been buying or selling shares of Oruka Therapeutics?

In the last ninety days, Arjun Agarwal has sold $1,294,839.33 of Oruka Therapeutics stock. Most recently, Arjun Agarwal sold 395 shares of the business's stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.69, for a transaction totalling $27,527.55. Following the completion of the sale, the senior vice president now directly owns 16,899 shares of the company's stock, valued at $1,177,691.31. Learn More on Arjun Agarwal's trading history.

Who are Oruka Therapeutics' active insiders?

Oruka Therapeutics' insider roster includes Arjun Agarwal (SVP), Carl Dambkowski (Director), Joana Goncalves (Chief Medical Officer), and Lawrence Klein (CEO). Learn More on Oruka Therapeutics' active insiders.

Are insiders buying or selling shares of Oruka Therapeutics?

In the last year, insiders at the sold shares 16 times. They sold a total of 214,585 shares worth more than $12,571,684.35. The most recent insider tranaction occured on June, 15th when SVP Arjun Agarwal sold 395 shares worth more than $27,527.55. Insiders at Oruka Therapeutics own 23.5% of the company. Learn More about insider trades at Oruka Therapeutics.

Information on this page was last updated on 6/15/2026.

Arjun Agarwal Insider Trading History at Oruka Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/15/2026Sell395$69.69$27,527.5516,899View SEC Filing Icon  
6/12/2026Sell9,459$69.72$659,481.4817,294View SEC Filing Icon  
5/18/2026Sell10,290$59.07$607,830.3016,406View SEC Filing Icon  
3/16/2026Sell395$41.30$16,313.5018,863View SEC Filing Icon  
See Full Table

Arjun Agarwal Buying and Selling Activity at Oruka Therapeutics

This chart shows Arjun Agarwal's buying and selling at Oruka Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Oruka Therapeutics Company Overview

Oruka Therapeutics logo
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Read More

Today's Range

Now: $68.86
Low: $67.71
High: $71.72

50 Day Range

MA: $63.71
Low: $53.31
High: $76.39

2 Week Range

Now: $68.86
Low: $10.77
High: $91.00

Volume

1,002,319 shs

Average Volume

1,168,775 shs

Market Capitalization

$4.15 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A